Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
The Neuromuscular Junction01:19

The Neuromuscular Junction

The nervous system consists of complex motor neuron circuits, including upper motor neurons originating from the cerebral cortex and lower motor neurons starting in the spinal cord, coordinating both voluntary and involuntary movements. Among these, somatic motor neurons activate skeletal muscles and are classified into alpha, beta, and gamma types. Alpha neurons are vital for voluntary movement coordination, while gamma neurons adjust muscle spindle sensitivity, and the function of beta...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Access to care for adults living with spinal muscular atrophy in the UK.

BMJ neurology open·2026
Same author

Relative frequencies of muscle specific kinase antibody myasthenia in 46 centres worldwide.

Brain : a journal of neurology·2026
Same author

"Hit Hard, Hit Early"-Should We Apply This in Myasthenia Gravis?

Journal of clinical neuromuscular disease·2025
Same author

Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update).

Practical neurology·2025
Same author

Genetic Insights and Diagnostic Challenges in Highly Attenuated Lysosomal Storage Disorders.

Genes·2025
Same author

Immunotherapy responsive startle with antibodies to voltage gated potassium channels.

BMJ case reports·2025
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

Autoimmune mediated neuromuscular junction defects.

Maria Elena Farrugia1, Angela Vincent

  • 1Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK. m.e.farrugia@doctors.org.uk

Current Opinion in Neurology
|July 24, 2010
PubMed
Summary
This summary is machine-generated.

Antibody-mediated neuromuscular junction disorders, like myasthenia gravis, are rising. Advances in serological assays and understanding pathogenicity are improving diagnosis and leading to newer therapies.

More Related Videos

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
08:41

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions

Published on: August 14, 2021

Related Experiment Videos

Last Updated: Jun 10, 2026

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy
11:03

Characterization of Neuromuscular Junctions in Mice by Combined Confocal and Super-Resolution Microscopy

Published on: December 8, 2021

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy
12:18

The Neuromuscular Junction: Measuring Synapse Size, Fragmentation and Changes in Synaptic Protein Density Using Confocal Fluorescence Microscopy

Published on: December 26, 2014

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions
08:41

Dissection of Single Skeletal Muscle Fibers for Immunofluorescent and Morphometric Analyses of Whole-Mount Neuromuscular Junctions

Published on: August 14, 2021

Area of Science:

  • Neurology
  • Immunology
  • Pathogenesis

Background:

  • Antibody-mediated disorders of the neuromuscular junction are increasingly recognized.
  • Myasthenia gravis incidence is rising, particularly in older adults.
  • Understanding the pathogenesis of these conditions is crucial for effective management.

Purpose of the Study:

  • To review recent advances in the pathogenesis of antibody-mediated neuromuscular junction disorders.
  • To summarize findings on clinical assessment tools.
  • To discuss current and emerging treatment strategies.

Main Methods:

  • Literature review of recent studies on neuromuscular junction disorders.
  • Analysis of clinical assessment tools and their validation.
  • Evaluation of therapeutic interventions, including immunosuppression and novel agents.

Main Results:

  • Rising incidence of myasthenia gravis, especially in those over 50.
  • Uncertainty regarding the mechanism of muscle specific tyrosine kinase (MuSK) antibody positive myasthenia gravis.
  • Development of reliable clinical assessment tools like the myasthenia gravis composite score.
  • Immunosuppression remains standard; rituximab and complement inhibitors show promise.
  • Improved diagnostic utility of antibodies in Lambert-Eaton myasthenic syndrome (LEMS) and Guillain-Barré syndrome (GBS).

Conclusions:

  • Advances in serological assays, especially cell-based assays, enhance diagnosis.
  • Improved understanding of pathogenicity facilitates the application of novel therapies.
  • Continued research is vital for refining diagnosis and treatment of these disorders.